Feature|Articles|January 22, 2025

Pending FDA Decisions in Neurology to Watch in the First Half of 2025

Author(s)Marco Meglio, Isabella Ciccone, MPH

Take a look at some of the most-anticipated FDA pending approvals expected in 2025 that researchers and clinicians in neurology should keep an eye out on.

Several treatment decisions are anticipated in the first half of 2025 across various neurological specialties, including movement disorders, neuromuscular conditions, headache and migraine, epilepsy, and more. With the constant activity in the clinical drug pipeline, staying informed about the latest approvals can be challenging.